You're probably in one of two places right now. Either a senior banker asked you to turn around an accretion dilution model before comments, or you're staring at a blank Excel sheet knowing the first question from management will be brutally simple: does this deal increase EPS or not?
That question sounds narrow, but it drives a surprising amount of M&A work. A clean accretion dilution model gives you a fast answer. A thorough one shows whether the answer is credible. That difference matters because the spreadsheet can be technically correct and still tell a misleading story if the synergy build, financing assumptions, or one-time adjustments are too generous.
Table of Contents
Why the Accretion Dilution Model Matters in M&A
It is 10:30 p.m., the buyer wants an answer before the board call, and the first question is rarely, “What is the long-term intrinsic value impact?” It is usually, “Is this deal accretive next year?” That is why the accretion dilution model sits near the center of live M&A work. It converts a messy transaction into one output the CEO, board, and investors can all react to quickly: pro forma EPS versus standalone EPS.
At a basic level, the test is straightforward. A deal is accretive if post-deal EPS is higher than the acquirer's standalone EPS, and dilutive if it is lower. In practice, the model matters because it forces you to tie together valuation, financing, accounting, and operating assumptions in one place. That is also why it gets abused. Small changes to synergies, close timing, purchase accounting, or the debt-stock mix can flip the headline result.
Boards care about that headline because EPS impact affects how the deal will be received on announcement. An economically sound transaction can still trade badly if near-term dilution is worse than expected. The reverse is also true. A weak deal can be dressed up as accretive if management pushes aggressive cost saves, ignores integration friction, or chooses assumptions that flatter year one EPS.
Use the model for what it is: a decision screen and a pressure test.
A good model helps answer three practical questions fast:
Can management defend the deal in public? If EPS is dilutive in the first year or two, you need a clear explanation for why shareholders should accept that trade-off.
Does the financing structure make sense? Cash, debt, and stock each change the math differently through interest expense, foregone interest income, and share issuance.
Is the price doing too much work? If the deal only turns accretive under optimistic assumptions, the issue is often valuation, not Excel.
Analysts also use a quick shortcut for all-stock deals. If the buyer trades at a higher P/E multiple than the target, issuing stock to buy the target's earnings is often accretive. If the buyer trades at a lower P/E, it is often dilutive, as explained in this overview of the all-stock P/E shortcut. The shortcut is useful for getting oriented in the first few minutes of a deal discussion.
It is not enough for real work.
The moment you add debt, cash, synergies, amortization, transaction fees, or integration costs, the shortcut stops being reliable. That is where junior bankers get tripped up. They memorize the rule, then miss the fact that a “headline accretive” deal may depend on synergies that arrive late, financing costs that are understated, or adjustments that disappear after the merger closes.
The core value of the accretion dilution model is not the accretion label itself. It is the discipline of building a defensible view of what the buyer is effectively paying, how the deal is funded, and which assumptions are carrying the answer. If you build it that way, the model does more than produce EPS. It helps you see how a deal is sold, and where it can be manipulated.
Assembling Your Model Inputs
At 11 p.m., the model is showing accretion and the VP wants numbers for the morning update. Before anyone trusts that output, the first question is simple. What did you feed the model? In live deal work, weak inputs create more bad calls than bad formulas.
The inputs tab is where analysts either control the model or lose control of it. A clean setup lets you trace every number to a filing, a management case, or a judgment call. A messy setup hides the assumptions that are driving the outcome, which is exactly how an aggressive deal case gets sold as “just the math.”
What you need before you touch formulas
Build the model from two standalone companies first. You are trying to answer four practical questions: what the buyer earns today, what the target contributes, what the buyer is paying, and how the purchase is funded.
Use this as your working input list:
Acquirer net income: Use the earnings figure that will support standalone EPS. Be explicit about whether you are using LTM, last fiscal year, or forward estimates.
Acquirer diluted shares: Use fully diluted shares, not basic shares. That single choice can make a marginal deal look cleaner than it is.
Target net income: Start with the target's standalone earnings before synergies, fees, financing effects, and purchase accounting.
Target equity value: Calculate share price times diluted shares outstanding. Confirm whether options, RSUs, or in-the-money convertibles need to be included.
Target enterprise value: Add debt, preferreds, and other debt-like items to equity value, then subtract cash if your definition of EV does so. This is often where new analysts miss pension deficits, leases, or minority interests.
Consideration mix: Split the purchase price between cash, debt, and stock. This drives both financing cost and share dilution.
Debt assumptions: If the deal uses new debt, set the amount, pricing, fees, and amortization assumptions clearly.
Foregone cash yield: If the buyer uses on-balance-sheet cash, include the lost interest income. Buyers like to ignore this when pitching cash-funded deals.
Synergies: Separate cost synergies, revenue synergies, one-time savings, and timing. If management gives you one big number with no ramp, press on it.
Intangible amortization and integration costs: These are common pressure points in fairness discussions and board materials because they can shift near-term EPS meaningfully.
One rule helps avoid half the review comments. Label each input as historical, street, management, or banker assumption.
Where analysts usually source the inputs
You will pull these numbers from different places, and they do not always line up neatly. Reporting dates differ. Definitions differ. Share counts differ between the cover page, the treasury stock method schedule, and the merger agreement. Part of the job is reconciling those differences before they flow into EPS.
| Input | Typical place to find it | What to check |
|---|---|---|
| Net income and diluted shares | 10-K, 10-Q, earnings materials | Reporting period, nonrecurring items, diluted share method |
| Share price and shares outstanding | Market data, filings, merger agreement | Fully diluted count, option treatment, latest unaffected price |
| Debt and cash | Balance sheet, debt footnotes, lender materials | Debt-like items, cash trapped overseas, financing fees |
| Deal mix | Merger announcement, term sheet, board materials | Fixed value vs fixed exchange ratio, rollover equity, seller elections |
| Synergies and integration assumptions | Management case, banker materials, diligence findings | Timing, one-time costs, owner, and evidence for each line item |
The best source is not always the most recent PDF. For share count, debt-like items, and transaction structure, the merger agreement and draft sources-and-uses often matter more than the latest investor presentation.
Input discipline that saves time later
Good input discipline is less about neat formatting and more about auditability. If the MD asks why accretion dropped by 40 basis points after comments, you should be able to point to one revised assumption in seconds.
A few habits matter:
Date every market-driven input: Share price, debt pricing, and cash balances move. If the timing is mixed, the purchase price and financing case stop matching.
Keep raw data separate from adjustments: Filing-based net income should sit apart from your normalization assumptions, synergy ramps, and purchase accounting.
Show units clearly: Dollars, millions, per-share figures, and percentages get mixed up constantly in fast-moving deal models.
Flag circular items early: Debt sizing can depend on fees, fees can depend on debt sizing, and interest expense can change the EPS output enough to matter.
Write down assumption ownership: If a synergy number came from management and not diligence, say so. That note can matter more than the number itself.
This is also where skepticism belongs. A model can be technically correct and still economically weak if the inputs are tilted. If the deal only works with full synergies in year one, a low borrowing cost, no meaningful dis-synergies, and a favorable share count convention, the issue is not Excel. The issue is the case being presented.
Treat the inputs tab like a working record of the deal, not a staging area for formulas. That is how you build a model that survives comments, supports an investment committee discussion, and helps you spot where the answer is being pushed.
Building the Accretion Dilution Model in Excel
You are in a live sell-side process. The buyer's team sends comments at 11:30 p.m., the MD wants a revised accretion view before midnight, and the output changes because one financing mix assumption moved. If your Excel model is built as a single chained calculation, you will waste time tracing cells. If it is built as a clear bridge from standalone earnings to pro forma EPS, you can update the case fast and explain exactly what changed.
That is the standard to aim for. The model is not just supposed to produce an answer. It has to show where the answer comes from, which assumptions are doing the work, and where someone could be pushing the case.
A simple process map helps before you start wiring formulas.
Recommended sheet structure
Keep the workbook modular. A practical structure usually looks like this:
Inputs and assumptions
Purchase price and sources of funds
Share issuance and financing
Pro forma net income bridge
EPS summary with accretion or dilution output
Sensitivity tables
This structure speeds up review. It also makes it harder to bury aggressive assumptions inside the mechanics. In a real deal, that matters.
The core calculation path
The model should flow in the same order that an associate or VP will review it.
Start with standalone acquirer earnings and share count. Add the target's contribution. Layer in financing effects, purchase accounting, and transaction items. Then divide pro forma net income by pro forma diluted shares and compare the result to standalone EPS.
The underlying math is straightforward:
Pro Forma EPS = (Acquirer Net Income + Target Net Income + After-Tax Synergies – After-Tax Incremental Interest Expense – After-Tax Foregone Interest Income – After-Tax New Intangible Amortization – After-Tax One-Time Integration Costs) / (Acquirer Diluted Shares + New Shares Issued)
Build that formula in separate rows, not in one long cell formula. A buyer can defend a bridge. No one wants to defend a black box.
The first two formulas are the base case:
Standalone EPS = Acquirer Net Income / Acquirer Diluted Shares
Pro Forma Shares = Acquirer Diluted Shares + New Shares Issued
Then build pro forma net income line by line. That layout does two jobs at once. It gives you a clean calculation path, and it shows whether accretion is coming from operating improvement, financial engineering, or assumptions that may not hold up in diligence.
Later in the section, if you want a walkthrough on mechanics, this video is useful for seeing the spreadsheet logic in action.
How to lay out the bridge in Excel
Use rows for each adjustment and columns for Year 1, Year 2, and Year 3. Keep the sequence intuitive and consistent with the transaction logic:
Acquirer net income
Plus target net income
Plus after-tax synergies
Less after-tax incremental interest expense
Less after-tax foregone interest income
Less after-tax amortization
Less after-tax integration costs
Equals pro forma net income
Then divide by pro forma diluted shares.
Finish with the output line:
Accretion or dilution % = (Pro Forma EPS / Standalone Acquirer EPS) – 1
A good model also separates recurring items from temporary ones. If year-one accretion depends on excluding integration costs but year-two economics are weak, your output may look better than the underlying deal.
What actually makes the Excel model strong
Strong accretion dilution models are easy to audit. Every adjustment should trace to a source, every formula should be readable, and every switch in the model should have a clear purpose. If you use scenario toggles for financing mix, synergy timing, or stock price, keep them visible and keep the formulas simple enough that another analyst can test them quickly.
Weak models usually fail in predictable ways. Hard-coded numbers sit inside formulas. Financing fees are spread inconsistently between debt and equity. New shares issued are linked to a stale share price. Transaction costs get buried in a catch-all row. Each of those mistakes can change the answer, and each one creates room to present the deal more favorably than the economics support.
If a VP asks why the deal is accretive, you should be able to point to three or four rows and explain it clearly. If you cannot, the model is not ready for a live process.
Calculating Pro Forma Adjustments and Synergies
A deal can look accretive at 11:00 a.m. and dilutive by lunch once someone tightens the synergy timing or updates the debt rate. That is why this section matters. The math is straightforward. The judgment inside the adjustments is where live deal work gets won, lost, or massaged.
The mechanics of pro forma net income
Your pro forma net income should reflect the earnings power of the combined company after closing, not a simple addition of buyer and target results. Breaking Into Wall Street's treatment of pro forma net income lays out the standard framework:
Pro Forma Net Income must be derived as Target's Net Income + Synergies – Interest Expense – Amortization of Intangibles – Tax Impact, where the tax impact specifically accounts for the tax shield from interest expense.
Build that logic line by line. Do not bury adjustments inside one net number. If a staffer, VP, or client asks what changed EPS, you should be able to point to a small set of rows and trace each one to a support schedule.
The tax treatment matters. If you subtract gross interest expense and stop there, you overstate the financing burden. If you tax-effect synergies inconsistently across years, you can manufacture year-one accretion that disappears under review.
The adjustments that deserve the most scrutiny
Three areas usually drive the answer. A fourth gets missed more often than it should.
| Adjustment | What to check | Why analysts challenge it |
|---|---|---|
| Synergies | Timing, run-rate, and whether they are cost or revenue based | Management teams can use them to support almost any headline |
| Interest expense | Debt amount, floating vs. fixed mix, and assumed rate | A small rate change can move EPS meaningfully |
| Intangible amortization | What assets are created in purchase accounting and their useful lives | It reduces reported earnings and is often underestimated early |
| Foregone interest income | Cash used, assumed yield, and whether trapped cash is excluded | Cash is not free if the buyer gives up income on it |
Synergies. Start with pre-tax synergies in the operating case, then apply taxes before they reach net income. Separate cost synergies from revenue synergies. Cost saves from procurement, overhead, or facilities consolidation are usually easier to diligence and easier to track after close. Revenue synergies deserve a higher burden of proof because they depend on sales execution, customer retention, pricing, and timing that management may not fully control.
Incremental interest expense. Model debt based on how the deal is financed, then apply an after-tax cost consistent with the buyer's tax profile. Be careful with floating-rate debt, delayed draw structures, and refinancing assumptions. In a live process, this line can change several times as financing terms move.
Intangible amortization. This is a purchase accounting issue, but it has real EPS impact. Customer relationships, developed technology, trademarks, and backlog can all create new amortizable assets. If the purchase price allocation is still preliminary, note that clearly and keep the assumption visible. Hiding a light amortization number in an early draft is a common way to make a deal look cleaner than it is.
Foregone interest income on cash. If the acquirer funds part of the purchase price with balance sheet cash, include the income that cash would have earned. Analysts often skip this because no lender invoice shows up, but it is still an economic cost.
How to keep the synergy case honest
Do not plug a single annual synergy number into the model and call it done. Use a build that answers four questions: what the synergy is, who owns delivery, when it starts, and what it costs to achieve.
A simple schedule usually works better than a clever one. Break synergies into major buckets, phase them by year or quarter, and add a separate line for one-time costs required to capture them. If management says procurement savings start immediately but the integration plan assumes vendor contracts roll over in nine months, the model should reflect the delay.
That discipline matters because accretion/dilution models are often used as persuasion tools, not just valuation tools. The pressure is rarely on the EPS formula itself. The pressure sits in the assumptions package around synergy timing, dis-synergies, stranded costs, and integration spend.
Where analysts get misled
The model usually fails through assumption quality, not Excel mechanics.
Common pressure points are easy to recognize in live files. Synergies hit too early. Integration costs sit below the line or disappear after year one. Revenue synergies arrive with full margin and no ramp. Share issuance is based on an outdated stock price. Debt fees are treated inconsistently across sources and uses, amortization, and cash flow.
Presentation accretion is the result. The deal screens as accretive because the model assumes perfect execution and delayed pain.
A better test is simple. Ask whether the deal still works if synergies arrive later, integration costs come in higher, or financing terms tighten. If the answer flips quickly, call that out. Your job is not to defend the headline. Your job is to show what has to go right for the headline to be true.
Running Sensitivity Tables and Scenario Analysis
You send the draft model to the VP at 11:30 p.m. The headline says the deal is 3.2% accretive in Year 1. Ten minutes later the comments come back: What happens if rates are 100 basis points higher, synergies slip by two quarters, and the seller pushes price by another turn? If your file cannot answer that in minutes, the model is not ready.
Sensitivity work matters because headline accretion is easy to manufacture. A deal can screen well on one set of assumptions and fail the moment financing tightens or synergy timing moves out. Your job is to show how much room the deal has before the answer changes.
Build tables around the assumptions that actually move the answer
Start with the drivers that change the committee discussion, not the ones that are convenient to plug into Excel. In a live accretion/dilution model, that usually means purchase price, cost synergies, financing mix, and interest rate. Those four inputs explain a large share of why one banker calls a deal attractive and another calls it fragile.
Use a two-variable data table only after the model is clean and fully linked. Put accretion or dilution percentage in the output cell. Then test one valuation driver against one operating or financing driver. Good pairings include purchase price versus synergies, and debt mix versus interest rate. Keep the ranges realistic. A sensitivity grid is supposed to expose the breakpoints, not decorate the page.
A few practical rules help:
Test the negotiated range: If the bid is likely to move from 10.0x to 11.0x EBITDA, there is no value in a table that runs from 8.0x to 14.0x.
Match timing to the issue: If the actual risk is delayed synergy capture, sensitize the ramp by year or quarter, not just the total dollar amount.
Separate financing from operating cases: Higher debt and higher synergies can both improve EPS, but they carry very different execution risk.
Flag the flip point: Show where the deal turns dilutive. That is often the most important number on the page.
Treat interest rate risk as a live input, not a footnote
Debt-funded deals break faster than many early models suggest because financing assumptions get stale. Instead of citing a market statistic, build the model so rates can be shocked directly. Run at least a base rate, a moderate widening case, and a stressed case. Then check whether the transaction still works after fees, original issue discount, and the tax effect of interest expense are all flowing correctly.
This is also where people cut corners. They sensitize the headline borrowing rate but forget commitment fees, refinancing assumptions, or the mix between revolver, term loan, bonds, and bridge. In a real deal, those details change pro forma EPS. If you are using one blended debt cost for convenience, make that a conscious simplification and say so.
Sensitivity tables are not an Excel exercise. They are a pressure test on the assumptions management is selling.
Build scenario cases that reflect how deals actually go wrong
A banker, CFO, or board member usually absorbs scenarios faster than a 15 by 15 grid. Build at least three cases and make each one internally consistent.
Base case: Management case on pricing, financing, and synergy timing.
Upside case: Better entry price, faster cost takeout, cleaner integration, or lower borrowing cost.
Downside case: Price pressure, slower synergies, higher integration spend, and tighter debt terms.
Do not change one line and call it a downside case. Real downside cases come in packages. If synergies are delayed, integration costs often rise and stranded costs often stay longer. If rates move against you, lenders may also push for a different capital structure. Those correlations matter because they show whether the deal is resilient or only modeled to look accretive.
Present the cases in a short summary by year, with pro forma EPS, accretion or dilution percentage, and a few supporting drivers. If the deal is only accretive in the base case and barely so, say that plainly. That is usually the actual answer.
Interpreting the Output and Spotting Red Flags
The model is done. The harder part starts now.
You are no longer checking whether Excel works. You are judging whether the deal case holds up, or whether the model was arranged to produce a headline. "Accretive in Year 1" is a starting point, not a conclusion. In live M&A work, that label gets used to sell deals that deserve more pushback.
What the output actually means
The core bridge is simple:
Accretion or dilution % = (Pro Forma EPS / Standalone EPS) – 1
That answer tells you whether pro forma EPS is above or below the buyer's standalone EPS. It does not tell you whether the buyer paid a sensible price, whether the financing risk is acceptable, or whether the integration plan is believable.
Read the result with a deal lens, not just a math lens. A slightly accretive outcome can still be low quality if it depends on aggressive cost saves, a stretched purchase multiple, or cheap financing that may not be available when the deal launches. A Year 1 dilutive result can still be acceptable if the strategic logic is clear and the earnings profile improves for reasons you can defend. A highly accretive result often deserves the most scrutiny, because clean accretion is easy to manufacture on paper.
One question matters right away. What is driving the EPS change? If the answer is real operating improvement, that is one discussion. If the answer is a favorable stock-for-stock exchange ratio, optimistic synergy timing, or excluded costs, that is a very different one.
Red flags experienced reviewers catch quickly
The formulas are rarely the problem. The pressure points sit in the assumptions and in what the model leaves out.
A few warning signs come up again and again:
Synergies carry the entire result: If the deal is dilutive before synergies and only turns accretive after a full synergy build, you are underwriting execution, not current economics.
Costs to achieve are buried or separated from the headline bridge: Savings are only meaningful on a net basis. If management presents gross synergies and the model barely shows restructuring, systems, retention, or facility costs, challenge it.
Purchase accounting is treated lightly: Incremental D&A and intangible amortization can materially change reported earnings, especially in asset-heavy or IP-heavy deals.
Timing is too clean: Quarter-by-quarter ramps that start exactly when the model needs them usually reflect presentation logic, not integration reality.
Accretion comes from financing optics: Cheap debt, a high buyer P/E, or a stock mix that flatters EPS can make a mediocre deal look good without improving the business.
Share count assumptions are inconsistent: Treasury stock method errors, omitted dilution from management rollover, or missing convert impact can move the answer more than many new analysts expect.
In practice, management teams and bankers usually do not manipulate the model by changing one obvious formula. They shape the output through judgment calls around run-rate synergies, implementation timing, one-time costs, financing structure, and what gets excluded from "adjusted" earnings. That is why output review matters as much as model construction.
Questions that pressure-test the model fast
Use a short challenge list and make management answer each item directly.
| Question | What you're testing |
|---|---|
| How much of accretion exists before synergies? | Whether the deal works without a perfect integration story |
| What costs are required to get those synergies, and where are they shown? | Whether savings are net or gross |
| Which line items are excluded from adjusted earnings, and for how long? | Whether the presentation is cleaning up the headline too aggressively |
| How much of the EPS lift comes from capital structure rather than operating performance? | The quality of accretion |
| What assumptions came from management, and what was added by advisors? | Source credibility |
| What breaks first if the deal underperforms? | The real sensitivity, not the marketed one |
A good review goes one step further. Tie each answer back to the purchase price and the strategic claim. If the buyer is paying a full multiple and the model only works with fast cost takeout, then the key factor is integration discipline. If the deal screens accretive only because the buyer's stock trades at a richer multiple than the seller's, call that out plainly. It may still be financeable. It is not the same as saying the business combination is strong.
That is the standard to use. Build the model carefully, then audit the story it is trying to tell.
Conclusion Your Next Steps in Financial Modeling
A good accretion dilution model answers the headline question quickly. A strong one does more than that. It shows exactly how the answer was produced, which assumptions matter most, and where the weak points are.
That's the standard you should aim for. Keep the build transparent. Keep financing logic separate from operating logic. Tax-effect the right items. Use diluted shares. Stress-test the assumptions that can flip the result. Above all, don't confuse an accretive output with proof that the acquisition is economically smart.
If you're practicing, build the model from scratch a few times with different consideration mixes and financing structures. Then rebuild it with a more skeptical synergy case. That second pass is usually where the learning happens.
The accretion dilution model is one of the first M&A models analysts are expected to handle well because it sits at the intersection of valuation, accounting, and capital structure. Once you're comfortable here, the next useful step is to deepen into full merger models, then branch into DCF and LBO work. Those models answer different questions, but they all reward the same habits: clean inputs, visible assumptions, and skepticism about outputs that look too good.
If your team is building internal finance tools, always-on research agents, or workflow automation around models and deal materials, Sokko is worth a look. It hosts always-on AI agents on isolated machines, supports runtimes like Hermes, OpenClaw, Paperclip, OpenSRE, and Cursor, and gives you live terminal access, Markdown-based configuration, shared persistent memory, and regional US or EU deployment options. For teams that want agent infrastructure without babysitting servers, it's a practical way to run production-grade AI workflows.